A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer

ADVERSE EVENT: Decreased abiraterone exposure after introducing carbamazepine. DRUGS IMPLICATED: Abiraterone acetate and carbamazepine. THE PATIENT: A 65‐year‐old man with metastatic castration resistant prostate cancer, was treated with abiraterone acetate and prednisolone, and received concomitant...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Clin Pharmacol
Egile Nagusiak: Benoist, Guillemette E., van der Doelen, Maarten J., ter Heine, Rob, van Erp, Nielka P., Mehra, Niven
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Case Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5903233/
https://ncbi.nlm.nih.gov/pubmed/29384591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13532
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak